中晚期非手术治疗肺癌患者应用卡瑞利珠单抗联合立体定向体部放疗的有效性研究  

Study on the Effectiveness of Applying Carolizumab Combined with Stereotactic Body Radiotherapy in Patients with Intermediate and Advanced Non-Surgically Treated Lung Cancer

作　　者：刘英光[1] LIU Ying-guang(Radiotherapy Department,Chifeng City Hospital,Chifeng Inner Mongolia,024000,China)

机构地区：[1]赤峰市医院放疗科,内蒙古赤峰024000

出　　处：《中华养生保健》2024年第13期46-49,共4页CHINESE HEALTH CARE

摘　　要：目的评估卡瑞利珠单抗联合立体定向体部放疗(SBRT)在中晚期非手术治疗肺癌中对生存期及治疗安全性的影响价值。方法采用回顾性分析,选择2020年4月—2022年10月赤峰市医院放疗科收治的中晚期非手术治疗肺癌患者300例,根据临床治疗方式不同,分为对照组(150例,SBRT治疗)与研究组(150例,SBRT治疗基础上静脉注射卡瑞利珠单抗,3周/次,共计4次)。两组均治疗3个疗程(21 d为1个疗程)。收集两组临床信息对比治疗效果、治疗前后炎症因子(IL-6、IL-10)、肿瘤坏死因子(TNF-a)、血管内皮因子(bFGF、Ang-2、VEGF、MMP-9)变化情况、机体免疫状况(CD4+、CD8+、NK)及治疗期间不良反应。结果研究组治疗有效率高于对照组,IL-6、IL-10水平低于对照组,TNF-a水平高于对照组(P<0.05);研究组bFGF、Ang-2、VEGF、MMP-9均低于对照组(P<0.05);研究组干预后机体免疫T细胞亚群CD4+、CD8+、NK高于对照组(P<0.05);两组治疗不良反应比较,差异无统计学意义(P>0.05)。结论卡瑞利珠单抗联合立体定向体部放疗(SBRT)在中晚期非手术治疗肺癌中展现了较好的生存期延长和治疗安全性,可通过调节炎症因子、肿瘤坏死因子和血管内皮因子的水平,以及增强机体的免疫功能,达到更好的治疗效果和较低的不良反应,临床应用价值高。Objective Evaluate the value of the combination of Carolizumab and Stereotactic Body Radiotherapy(SBRT)on survival and treatment safety in the non-surgical treatment of advanced lung cancer.Methods Retrospective analysis was conducted on 300 patients with advanced non-surgical treatment of lung cancer admitted to the Radiotherapy Department of Chifeng City Hospital from April 2020 to October 2022.According to different clinical treatment methods,they were divided into a study group(150 cases,treated with SBRT)and a control group(150 cases,treated with intravenous injection of Carolizumab every three weeks,a total of four times).Both groups were treated for 3 courses(21 days per course).Collect two sets of clinical information to compare treatment effi cacy,changes in infl ammatory factors(IL-6,IL-10),tumor necrosis factor(TNF-a),vascular endothelial factors(bFGF,Ang-2,VEGF,MMP-9)before and after treatment,immune status(CD4+,CD8+,NK),and adverse reactions during treatment.Results The treatment eff ectiveness rate of the research group was higher than that of the control group,with lower levels of IL-6 and IL-10,and higher levels of TNF-a than the control group(P<0.05);The levels of bFGF,Ang-2,VEGF,and MMP-9 in the study group were lower than those in the control group(P<0.05);After intervention,the immune T cell subpopulations CD4+,CD8+,and NK in the study group were higher than those in the control group(P<0.05);There was no statistically significant difference in adverse reactions between the two groups(P>0.05).Conclusion Karelizumab combined with SBRT in the treatment of advanced non-surgical lung cancer can improve clinical treatment effi cacy,improve immune status,suppress tumor related infl ammatory reactions,and reduce the incidence of adverse reactions during treatment.It has high clinical application value.

关 键 词：卡瑞利珠单抗 立体定向体部放疗 中晚期 非手术治疗 肺癌 

分 类 号：R743.3[医药卫生—神经病学与精神病学]